EFFECT OF IL-2 GENE POLYMORPHISM T330G ON THE LEVEL OF CERTAIN LABORATORY MARKERS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS

Aim: To study the possible association of the T330G (rs2069762) polymorphism of the interleukin-2 (IL-2) gene with the levels of markers of endothelial dysfunction, systemic inflammation, and intestinal permeability in patients with type 1 diabetes mellitus (DM1). Materials and methods: The study included 90 patients with DM1. The T330G polymorphism of the IL-2 gene was genotyped by polymerase chain reaction. Concentrations of zonulin, lipopolysaccharide-binding protein (LBP), endothelin-1, transforming growth factor-β (TGF-β), C-reactive protein (CRP), bactericidal permeability enhancing protein (BPI), soluble CD14 receptors (sCD14), plasminogen activator inhibitor were determined in blood plasma by enzyme immunoassay-1 (PAI-1) and angiotensin-2. The statistical analysis was carried out using the Kruskal-Wallis criterion. Results: It was found that carriers of the TT genotype had statistically significantly higher levels of angiotensin-2 compared with carriers of the GG genotype (p=0.021). Patients with the TT genotype also had higher concentrations of TGF-β compared with the heterozygous TG group (p=0.015). For the other markers studied (zonulin, LBP, endothelin-1, CRP, BPI, sCD14, PAI-1), no statistically significant differences were found between the groups depending on the IL-2 T330G genotype. Conclusion: The T330G polymorphism of the IL-2 gene is associated with changes in angiotensin-2 and TGF-β levels in patients with DM1. This indicates the potential role of this genetic variant in modulating the activity of the renin-angiotensin system and pathways of fibrogenesis, which may contribute to the development of vascular complications of diabetes mellitus.

1. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet,

2. , Vol. 383, no. 9911, pp. 69-82.

3. Bluestone J.A., Herold K.C., Eisenbarth G.S. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature, 2010, Vol. 464, no. 7293, pp. 1293–1300.

4. Bottinger E.P. TGF-beta in renal injury and disease. Seminars in Nephrology, 2007, Vol. 27, no. 3, pp. 309–320.

5. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. Journal of Experimental Medicine, 2003, Vol. 198, no. 12, pp. 1875–1886.

6. Cole J.B., Florez J.C. Genetics of diabetes mellitus and diabetes complications. Nature Reviews Nephrology, 2020, Vol. 16, no. 7, pp. 377–390.

7. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Physiological Reviews, 2013, Vol. 93, no. 1, pp. 137–188.

8. Hoffmann S.C., Stanley E.M., Cox E.D., et al. Association of a promoter polymorphism of the IL-2 gene with severity of disease in rheumatoid arthritis. Genes & Immunity, 2002, Vol. 3, no. 8, pp. 480–484.

9. Kvakan H., Kleinewietfeld M., Qadri F., et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation, 2009, Vol. 119, no. 22, pp. 2904–2912.

10. Lavoie J.L., Sigmund C.D. Minireview: Overview of the renin-angiotensin system—an endocrine and paracrine system. Endocrinology, 2003, Vol. 144, no. 6, pp. 2179–2183.

11. Long S.A., Cerosaletti K., Bollyky P.L., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes, 2010, Vol. 59, no. 2, pp. 407–415.

12. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity, 2010, Vol. 33, no. 2, pp. 153–165.

13. Meng X.M., Nikolic-Paterson D.J., Lan H.Y. TGF-β: The master regulator of fibrosis. Nature Reviews Nephrology, 2016, Vol. 12, no. 6, pp. 325–338.

14. Ruiz-Ortega M., Lorenzo O., Rupérez M., et al. Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension, 2001, Vol. 38, no. 6, pp. 1382–1387.

15. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nature Reviews Immunology, 2010, Vol. 10, no. 7, pp. 490–500.

16. Todd J.A. Etiology of type 1 diabetes. Immunity, 2010, Vol. 32, no. 4, pp. 457–467.

17. Vaarala O. Gut microbiota and type 1 diabetes. Reviews in Diabetic Studies, 2012, Vol. 9, no. 4, pp. 251–259.

18. Zeng Z., Duan Z., Zhang R., et al. Association of interleukin-2 −330 T/G polymorphism with autoimmune diseases: A meta-analysis. PLoS ONE, 2013, Vol. 8, no. 12, e81844.